arrow
F

Francesca Montagnani

University of Siena
H指数:37
被引数:6,137

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cumulative exposure to integrase inhibitors and metabolic factors as independent predictors of severe hepatic steatosis in people with HIV

整合酶抑制剂和代谢因素的累积暴露作为HIV感染者严重肝脂肪变性的独立预测因子

2026-10-210
OAAI
Memory B cell response to SARS-CoV-2 vaccination in people with heart and lung transplantation: Identification of associated clinical factors

心肺移植受者对SARS-CoV-2疫苗接种的记忆B细胞反应:相关临床因素的鉴定

2026-09-070
OAAI
Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature

使用头孢地尔治疗肺移植术后肺炎:一个病例系列及文献见解

2025-12-190
PRE
Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153

抗原非依赖性鉴定靶向OPG153的痘病毒广谱中和抗体

2025-12-100
PRE
Cartoon: multicenter prospective observational study of Cardiovascular Toxicity of Trifluridine/Tipiracil in metastatic colorectal cancer

漫画:三氟尿idine/替吡拉塞在转移性结直肠癌中心血管毒性的多中心前瞻性观察研究

2025-07-011
OAAI
Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance

革兰阴性菌引起的老年住院患者尿路感染:在抗菌药物耐药时代的流行病学、临床特征及预后

2025-06-110
OAAI
Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients

SARS-CoV-2 mRNA疫苗接种后的转录组分析揭示了低应答者血液透析患者中的特异性基因特征

2025-04-300
OA
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses
2024-09-011
OAAI
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study

美罗培南vabobactam治疗kpc-kp感染患者的预后和死亡率预测因素: 一项观察性多中心研究

2024-05-087
OAAI
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant

mRNA或腺病毒载体疫苗的同源或异源给药对SARS-CoV-2 Omicron变体显示出相当的免疫原性和有效性

2024-04-024
OA
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry
2024-02-075
OAAI